Pi-Cardia has concluded the patient enrolment of the pivotal study of its ShortCut device, which is part of the company’s leaflet modification product portfolio.

ShortCut is claimed to be the world’s first dedicated device designed for splitting the leaflets of pre-existing valves to facilitate safe transcatheter aortic valve replacement (TAVR) in patients with a risk of coronary obstruction.

The study took place at 20 TAVR centres in Europe and the US.

It was led by doctors Susheel Kodali (New York Presbyterian/Columbia University, New York, US), Danny Dvir (Sha’are Zedek, Jerusalem, Israel) and Didier Tchétché (Clinique Pasteur, Toulouse, France).

The trial involved 60 subjects undergoing valve-in-valve procedures. ShortCut was used in these patients as a preceding step to TAVR implantation.

Central echo and CT core labs independently analysed the data.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pi-Cardia CEO Erez Golan said: “We are thrilled to have completed enrolment months ahead of schedule.

“This milestone not only validates our market models predicting a significant percentage of TAVR patients in need of leaflet modification, but it also means we should be able to commercialise ShortCut in the US and Europe as soon as 2024.”

The company’s leaflet modification product portfolio also includes the ShortCut Mitral to split leaflets in patients who are at risk of left ventricular outflow tract obstruction following TMVR.

Leaflex, also part of the portfolio, is a standalone, non-implant-based mechanical scoring device for restoring leaflet mobility and improving haemodynamics for aortic stenosis patients. Global clinical trials of Leaflex are currently in progress.